Stock Traders Purchase Large Volume of Call Options on Sarepta Therapeutic (SRPT)
Shares of Sarepta Therapeutic (NASDAQ:SRPT) saw unusually large options trading on Friday. Traders acquired 22,119 call options on the company, Analyst Ratings Network.com reports. This represents an increase of approximately 1,009% compared to the average daily volume of 1,995 call options.
In other Sarepta Therapeutic news, Director M Kathleen Behrens acquired 6,500 shares of Sarepta Therapeutic stock on the open market in a transaction dated Monday, September 16th. The shares were purchased at an average price of $37.04 per share, with a total value of $240,760.00. Following the acquisition, the director now directly owns 44,166 shares in the company, valued at approximately $1,635,909. The purchase was disclosed in a document filed with the SEC, which is available at this link.
A number of analysts have recently weighed in on SRPT shares. Analysts at Piper Jaffray Cos. upgraded shares of Sarepta Therapeutic (NASDAQ:SRPT) from a “neutral” rating to an “overweight” rating in a research note to investors on Friday. Separately, analysts at Deutsche Bank upgraded shares of Sarepta Therapeutic (NASDAQ:SRPT) from a “hold” rating to a “buy” rating in a research note to investors on Friday. They now have a $71.00 price target on the stock, up previously from $45.00. Finally, analysts at Stifel Nicolaus initiated coverage on shares of Sarepta Therapeutic (NASDAQ:SRPT) in a research note to investors on Thursday, September 5th. They set a “buy” rating and a $51.00 price target on the stock.
Six analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $52.78.
Shares of Sarepta Therapeutic (NASDAQ:SRPT) opened at 43.30 on Monday. Sarepta Therapeutic has a 52 week low of $13.99 and a 52 week high of $47.35. The stock has a 50-day moving average of $35.37 and a 200-day moving average of $36.14. The company’s market cap is $1.452 billion.
Sarepta Therapeutic (NASDAQ:SRPT) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.46) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.67) by $0.21. The company had revenue of $3.00 million for the quarter, compared to the consensus estimate of $5.08 million. The company’s quarterly revenue was down 73.2% on a year-over-year basis. Analysts expect that Sarepta Therapeutic will post $-3.24 EPS for the current fiscal year.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, is a biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of both rare and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.